Across TCGA pan-cancer cohorts, DNA2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DNA2 data layer compared with 28 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher DNA2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNA2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.
GBM and LSCC are the cancer types where DNA2 mass-spec protein most reproducibly stratifies survival.